专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

91. 发明申请

WO2014153004A1 SOLID POLYGLYCOL-BASED BIOCOMPATIBLE PRE-FORMULATION 审中-公开
标题翻译：基于固体聚合物的生物化学预处理
公开(公告)号：WO2014153004A1
公开(公告)日：2014-09-25
申请号：PCT/US2014/028622
申请日：2014-03-14
申请人： MEDICUS BIOSCIENCES LLC
发明人： ASKARI, Syed H. , CHOI, Yeon S. , WAN, Paul YuJen
IPC分类号： A61L27/58 , A61L27/52
CPC分类号： A61L26/0019 , A61K9/0024 , A61K9/06 , A61K31/00 , A61K31/155 , A61K31/505 , A61K31/573 , A61K31/635 , A61K31/728 , A61K31/785 , A61K31/795 , A61K33/00 , A61K35/28 , A61K45/06 , A61K47/00 , A61K47/10 , A61K47/34 , A61K49/0404 , A61K49/0409 , A61K49/0457 , A61L26/0066 , A61L26/008 , A61L27/18 , A61L27/3604 , A61L27/3695 , A61L27/52 , A61L27/54 , A61L2300/206 , A61L2300/404 , A61L2300/41 , A61L2400/06 , A61L2430/24 , A61L2430/34 , A61K2300/00 , C08L71/02
摘要： Provided herein are pre-formulations forming a biocompatible hydrogel polymer comprising at least one nucleophilic compound or monomer unit, at least one electrophilic compound or monomer unit, and optionally a therapeutic agent and/or viscosity enhancer. In some embodiments, the biocompatible hydrogel polymer covers a wound in a mammal and adheres to the surrounding skin tissue. In other embodiments, the hydrogel polymer is delivered into a joint space to treat joint disease or navicular disease.
摘要翻译：本文提供形成生物相容性水凝胶聚合物的预制剂，其包含至少一种亲核化合物或单体单元，至少一种亲电子化合物或单体单元，以及任选的治疗剂和/或粘度增强剂。在一些实施方案中，生物相容性水凝胶聚合物覆盖哺乳动物中的伤口并粘附到周围的皮肤组织。在其它实施方案中，将水凝胶聚合物递送至关节空间以治疗关节疾病或舟状病。

92. 发明申请

WO2013103707A1 LIGAND-TARGETED MOLECULES AND METHODS THEREOF 审中-公开
标题翻译：配体定向分子及其方法
公开(公告)号：WO2013103707A1
公开(公告)日：2013-07-11
申请号：PCT/US2013/020130
申请日：2013-01-03
申请人： INVICTUS ONCOLOGY PVT. LTD. , SENGUPTA, Shiladitya
发明人： SENGUPTA, Shiladitya , HUSSAIN, Sazid , PRAMANIK, Dipankar , ROY, Monideepa , HOSSAIN, Seikh Samad
IPC分类号： A61K47/48 , A61P35/00
CPC分类号： A61K47/60 , A61K31/282 , A61K47/00 , A61K47/50 , A61K47/58 , A61K47/64 , A61K47/641 , A61K47/68 , A61K47/6803 , A61K47/6849 , A61K47/6883 , C07F15/0086
摘要： The present invention relates to ligand-targeted molecules and ligand drug conjugates (LDCs) comprising a ligand connected to a functional group, which is connected to a linker, wich in turn is bonded to a drug. The LDCs of the present invention also comprise platinum coordination complex wherein the platinum is connected to the linker through monocarboxylato and O→Pt coordinate bonds. The present invention also relates to methods for preparing these ligand drug conjugates. The present invention further relates to methods for the treatment of tumours using the ligand drug conjugates of the present invention.
摘要翻译：本发明涉及配体靶向分子和配体药物偶联物（LDC），其包含与连接到连接体的官能团连接的配体，其又结合到药物上。本发明的最不发达国家还包括铂配位络合物，其中铂通过单羧酸和O-> Pt配位键与连接体连接。本发明还涉及制备这些配体药物偶联物的方法。本发明还涉及使用本发明的配体药物偶联物治疗肿瘤的方法。

93. 发明申请

WO2012143576A3 COMPOUNDS FOR PREVENTING, REDUCING AND/OR ALLEVIATING ITCHY SKIN CONDITION(S) 审中-公开
标题翻译：用于预防，减少和/或消除眼科皮肤病症的化合物（S）
公开(公告)号：WO2012143576A3
公开(公告)日：2013-05-02
申请号：PCT/EP2012066442
申请日：2012-08-23
申请人： SYMRISE AG , SCHMAUS GERHARD , KROHN MICHAEL , SOMBROEK DIRK , HAUSTEDT LARS OLE , KLUGE GRIT , KOCH OSKAR , KOEHLER ANTJE
发明人： SCHMAUS GERHARD , KROHN MICHAEL , SOMBROEK DIRK , HAUSTEDT LARS OLE , KLUGE GRIT , KOCH OSKAR , KOEHLER ANTJE
IPC分类号： A61K31/12 , A61K8/35 , A61P17/04 , A61Q19/00
CPC分类号： A61K31/12 , A23G4/12 , A61K8/35 , A61K9/0014 , A61K9/0063 , A61K9/06 , A61K9/1075 , A61K9/2018 , A61K45/06 , A61K47/00 , A61K2800/10 , A61K2800/75 , A61Q5/00 , A61Q5/002 , A61Q5/004 , A61Q5/006 , A61Q5/02 , A61Q5/04 , A61Q5/10 , A61Q5/12 , A61Q11/00 , A61Q13/00 , A61Q15/00 , A61Q17/04 , A61Q19/00 , A61Q19/004 , A61Q19/007 , A61Q19/02 , A61Q19/04 , A61K2300/00
摘要： The present invention primarily relates to the use of one or more specific compounds and/or one or more respective salt(s) thereof for preventing, reducing or alleviating itchy skin condition(s), and/or as PAR-2 antagonist. Furthermore, the present invention relates to compositions (products or, respectively, formulations), in particular for topical administration, preferably cosmetic or pharmaceutical compositions, in particular for preventing, reducing or alleviating one or more itchy skin conditions and/or for providing a PAR-2 antagonistic effect, comprising or consisting of an effect amount of such compound(s) and/or salt(s) and one or more cosmetically and/or pharmaceutically acceptable carriers.
摘要翻译：本发明主要涉及一种或多种特定化合物和/或其一种或多种相应的盐用于预防，减轻或缓解瘙痒的皮肤状况和/或作为PAR-2拮抗剂的用途。此外，本发明涉及组合物（产品或分别为制剂），特别是用于局部施用，优选化妆品或药物组合物，特别是用于预防，减少或减轻一种或多种瘙痒皮肤病症和/或提供PAR -2拮抗作用，其包含或由其作用的一种或多种化合物和/或盐和一种或多种化学和/或药学上可接受的载体组成。

94. 发明申请

WO2012002759A3 MICROVESICLES DERIVED FROM CELL PROTOPLAST, AND USE THEREOF 审中-公开
标题翻译：源自细胞原生质体的微生物及其用途
公开(公告)号：WO2012002759A3
公开(公告)日：2012-05-03
申请号：PCT/KR2011004820
申请日：2011-06-30
申请人： AEON MEDIX INC , GHO YONG SONG , JANG SU CHUL , KIM YOON KEUN , KIM OH YOUN
发明人： GHO YONG SONG , JANG SU CHUL , KIM YOON KEUN , KIM OH YOUN
IPC分类号： A61K9/133 , A61K35/74 , A61K47/40 , A61K49/08 , A61K49/18
CPC分类号： A61K47/48838 , A61K9/127 , A61K9/5063 , A61K38/162 , A61K38/1825 , A61K38/1866 , A61K38/20 , A61K38/21 , A61K39/0011 , A61K39/02 , A61K39/39 , A61K45/06 , A61K47/00 , A61K47/10 , A61K47/40 , A61K47/46 , A61K47/6917 , A61K49/0017 , A61K49/0045 , A61K49/0097 , A61K2039/55555 , B82Y5/00 , C07K14/71 , C07K2319/00 , Y10S977/773
摘要： The present invention relates to microvesicles derived from a protoplast which is a bacterial, archaea, fungal or plant cell or the like from which a cell wall is removed. The microvesicles derived from a protoplast of the present invention enables free loading of a material necessary for diagnosis, treatment, vaccine, target induction, cell membrane fusion with a target cell, reduction of in vivo and in vitro side effects, stability improvement, and the like, and allows the therapeutic material, the diagnostic material and/or the vaccine material to be delivered specifically to a specific tissue or cell.
摘要翻译：本发明涉及源自原生质体的微泡，所述原生质体是除去细胞壁的细菌，古细菌，真菌或植物细胞等。来源于本发明的原生质体的微泡使得能够自由加载诊断，治疗，疫苗，靶诱导，与靶细胞的细胞膜融合，体内和体外副作用的减少，稳定性改善以及并且允许将治疗材料，诊断材料和/或疫苗材料特异性递送至特定的组织或细胞。

95. 发明申请

WO2007095627A2 PQS: A NEW HYDROTROPE FOR SOLUBILIZING LIPOPHILIC COMPOUNDS IN WATER 审中-公开
标题翻译： PQS：一种用于溶解水中的锂离子化合物的新型水解剂
公开(公告)号：WO2007095627A2
公开(公告)日：2007-08-23
申请号：PCT/US2007062257
申请日：2007-02-15
申请人： ZYMES LLC , LIPSHUTZ BRUCE H
发明人： LIPSHUTZ BRUCE H
CPC分类号： A61K47/10 , A61K47/00
摘要： The present invention provides a solubilizing agent of the general formula: ,(L2)z4 (Y2)Z2 (L1)z3 (Y1)zi wherein R 11 , R 12 and R 13 are members independently selected from H, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl and substituted or unsubstituted heteroaryl. Ll and L2 are linker moieties, which are members independently selected from substituted or unsubstituted alkyl and substituted or unsubstituted heteroalkyl. Yl and Y2 are hydrophilic moieties, which are members independently selected from polyethers, polyalcohols and derivatives thereof. Zl, Z2, Z3 and Z4 are members independently selected from 0 and 1, wherein at least one of Zl and Z2 is 1.
摘要翻译：本发明提供通式为：（L2）z4（Y2）Z2（L1）z3（Y1）zi的增溶剂，其中R 11，R 12和 R 13是独立地选自H，取代或未取代的烷基，取代或未取代的杂烷基，取代或未取代的环烷基，取代或未取代的杂环烷基，取代或未取代的芳基和取代或未取代的杂芳基的成员。 L1和L2是连接体部分，其是独立地选自取代或未取代的烷基和取代或未取代的杂烷基的成员。 Y 1和Y 2是亲水部分，其是独立地选自聚醚，多元醇及其衍生物的成员。 Z 1，Z 2，Z 3和Z 4是独立地选自0和1的成员，其中Z 1和Z 2中的至少一个是1。

96. 发明申请

WO2006044840A8 SOLUBLE ZCYTOR21, ANTI-ZCYTOR21 ANTIBODIES AND BINDING PARTNERS AND METHODS OF USING IN INFLAMMATION 审中-公开
标题翻译：可溶性ZCYTOR21，抗ZCYTOR21抗体和结合合作伙伴及其在炎症中的使用方法
公开(公告)号：WO2006044840A8
公开(公告)日：2006-07-06
申请号：PCT/US2005037332
申请日：2005-10-18
申请人： ZYMOGENETICS INC , GAO ZEREN , KUESTNER ROLF E , APPLEBY MARK W , LEWIS KATHERINE E , MCKERNAN PATRICIA A , OKADA SHANNON L , TAFT DAVID W , KUIJPER JOSEPH L , JASPERS STEPHEN R , LEVIN STEVEN D
发明人： GAO ZEREN , KUESTNER ROLF E , APPLEBY MARK W , LEWIS KATHERINE E , MCKERNAN PATRICIA A , OKADA SHANNON L , TAFT DAVID W , KUIJPER JOSEPH L , JASPERS STEPHEN R , LEVIN STEVEN D
IPC分类号： C07K14/715
CPC分类号： C07K14/7155 , A61K38/00 , A61K39/395 , A61K47/00 , A61K47/60 , C07K14/54 , C07K16/00
摘要： The present invention relates ZcytoR21 antagonists, such as soluble receptors and anti-ZcytoR21 antibodies, that are useful in blocking, inhibiting, reducing, antagonizing or neutralizing the activity of IL-17C. IL-17C is a cytokine that is involved in inflammatory processes and human disease. ZcytoR21 is a receptor for IL-17C. The present invention includes soluble ZcytoR21, anti-ZcytoR21 antibodies and binding partners, as well as methods for antagonizing IL-17C using such soluble receptors, antibodies and binding partners.
摘要翻译：本发明涉及可用于阻断，抑制，降低，拮抗或中和IL-17C活性的ZcytoR21拮抗剂，例如可溶性受体和抗ZcytoR21抗体。 IL-17C是涉及炎症过程和人类疾病的细胞因子。 ZcytoR21是IL-17C的受体。本发明包括可溶性ZcytoR21，抗ZcytoR21抗体和结合配偶体，以及使用这种可溶性受体，抗体和结合配偶体拮抗IL-17C的方法。

97. 发明申请

WO2006044840A2 SOLUBLE ZCYTOR21, ANTI-ZCYTOR21 ANTIBODIES AND BINDING PARTNERS AND METHODS OF USING IN INFLAMMATION 审中-公开
标题翻译：可溶性ZCYTOR21，抗ZCYTOR21抗体和结合合作伙伴及其在炎症中的使用方法
公开(公告)号：WO2006044840A2
公开(公告)日：2006-04-27
申请号：PCT/US2005037332
申请日：2005-10-18
申请人： ZYMOGENETICS INC , GAO ZEREN , KUESTNER ROLF E , APPLEBY MARK W , LEWIS KATHERINE E , MCKERNAN PATRICIA A , OKADA SHANNON L , TAFT DAVID W , KUIJPER JOSEPH L , JASPERS STEPHEN R , LEVIN STEVEN D
发明人： GAO ZEREN , KUESTNER ROLF E , APPLEBY MARK W , LEWIS KATHERINE E , MCKERNAN PATRICIA A , OKADA SHANNON L , TAFT DAVID W , KUIJPER JOSEPH L , JASPERS STEPHEN R , LEVIN STEVEN D
IPC分类号： C07K14/715
CPC分类号： C07K14/7155 , A61K38/00 , A61K39/395 , A61K47/00 , A61K47/60 , C07K14/54 , C07K16/00
摘要： The present invention relates ZcytoR21 antagonists, such as soluble receptors and anti-ZcytoR21 antibodies, t at are useful in blocking, inhibiting, reducing, antagonizing or neutralizing the activity of IL 17C. IL-17C is a cytokine that is involved in inflammatory processes and human disease. ytoR.21 is a receptor for IL-17C. The present invention includes soluble ZcytoR21, an i-ZcytoR21 antibodies and binding partners, as well as methods for antagonizing IL-1 C using such soluble receptors, antibodies and binding partners.
摘要翻译：本发明涉及可用于阻断，抑制，降低，拮抗或中和IL 17C活性的ZcytoR21拮抗剂，例如可溶性受体和抗ZcytoR21抗体。 IL-17C是涉及炎症过程和人类疾病的细胞因子。 ytoR.21是IL-17C的受体。本发明包括可溶性ZcytoR21，i-ZcytoR21抗体和结合配偶体，以及使用这种可溶性受体，抗体和结合配偶体拮抗IL-1C的方法。

98. 发明申请

WO2004071469A3 METHODS OF ADMINISTERING A DERMATOLOGICAL AGENT TO A SUBJECT 审中-公开
标题翻译：将一种皮肤药剂给予一个主体的方法
公开(公告)号：WO2004071469A3
公开(公告)日：2004-12-29
申请号：PCT/US2004000997
申请日：2004-01-14
申请人： TEIKOKU PHARMA USA INC , KOO JOHN , SHUDO JUTARO , SHIRAI SADANOBU
发明人： KOO JOHN , SHUDO JUTARO , SHIRAI SADANOBU
IPC分类号： A61F13/00 , A61K20060101 , A61K8/02 , A61K8/04 , A61K9/70 , A61Q19/00
CPC分类号： A61K47/00 , A61K8/0208 , A61K8/042 , A61K9/0014 , A61K9/7023 , A61Q19/00
摘要： Methods for administering a dermatological agent to a subject are provided. In the subject methods an effective amount of a topical formulation of the dermatological agent is topically applied to a host. The topically applied formulation of dermatological agent is then occluded with a hydrogel patch, where a feature of the hydrogel patch is that it lacks a pharmaceutically active agent. Also provided are methods of treating a subject for a disease condition by administering a dermatological agent to the subject. Also provided are kits for use in practicing the subject methods. The subject methods and compositions find use in a variety of different applications.

99. 发明申请

WO2004067023A2 SURVIVIN-DERIVED PEPTIDES AND USE THEREOF 审中-公开
标题翻译：存活素衍生肽及其用途
公开(公告)号：WO2004067023A2
公开(公告)日：2004-08-12
申请号：PCT/DK2004/000062
申请日：2004-01-30
申请人： SURVAC A/S , STRATEN, Eivind, Per, Thor , ANDERSEN, Mads, Hald
发明人： STRATEN, Eivind, Per, Thor , ANDERSEN, Mads, Hald
IPC分类号： A61K38/17
CPC分类号： C07K14/4747 , A61K38/00 , A61K39/0011 , A61K39/002 , A61K39/39 , A61K47/00 , A61K47/51 , A61K2039/5154 , A61K2039/5158 , C07K14/4738 , G01N33/574 , G01N33/57484
摘要： MHC Class I-restricted peptides derived from the tumor associated antigen, survivin, which peptides are capable of binding to Class I HLA molecules at a high affinity, capable of eliciting INF-γ-producing cells in a PBL population of a cancer patient and capable of in situ detection of cytotoxic T cells in a tumor tissue, therapeutic and diagnostic composition comprising the peptide and uses thereof.
摘要翻译： MHC I类限制性肽衍生自肿瘤相关抗原存活蛋白，所述肽能够以高亲和力与I类HLA分子结合，能够引发产生INF-γ的细胞癌症患者的PBL群并且能够原位检测肿瘤组织中的细胞毒性T细胞，包含该肽的治疗和诊断组合物及其用途。

100. 发明申请

WO2004005533A2 SOL-GEL DERIVED BIOACTIVE GLASS POLYMER COMPOSITE 审中-公开
标题翻译： SOL-GEL衍生的生物玻璃聚合物复合材料
公开(公告)号：WO2004005533A2
公开(公告)日：2004-01-15
申请号：PCT/US2003/021962
申请日：2003-07-10
申请人： UNIVERSITY OF FLORIDA
发明人： HATCHER, Brian, M. , BRENNAN, Anthony , CUEVAS, Brian , SEEGERT, Charles
IPC分类号： C12Q
CPC分类号： A61K47/00 , A61K47/02 , A61K47/24 , A61K47/32 , A61L27/446 , A61L27/46 , A61L27/52
摘要： A bioactive sol-gel solution includes a biocompatible polymer, a gelable inorganic base material, and at least one calcium and phosphorous molecular species. The base material can be an alkoxide, such as TEOS. The polymer acts as a viscosity modifier to the sol or gel, increases the viscosity range over which fibers can be sprayed or spun, and broadens the time period over which fibers can be sprayed or spun. A bioactive glass composite can be formed from the bioactive sol-gel solution, including a fibrous form. Fibers can serve as a scaffold for cell growth and in the repair of hard or soft tissue defects.
摘要翻译：生物活性溶胶 - 凝胶溶液包括生物相容性聚合物，可胶凝无机基材料和至少一种钙和磷分子种类。基材可以是醇盐，如TEOS。聚合物作为溶胶或凝胶的粘度调节剂，增加可以喷射或纺丝纤维的粘度范围，并且扩大可以喷涂或纺丝纤维的时间。生物活性玻璃复合物可以由生物活性溶胶 - 凝胶溶液形成，包括纤维形式。纤维可以作为细胞生长和修复硬组织或软组织缺陷的支架。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式